Kamada (KMDA) AI Stock Analysis

• Market Cap: $1.27B
• Dividend Yield: N/A
• Average Volume (3M): 62.86K
• Price to Earnings (P/E): 17.4
• Beta (1Y): 0.82
• Revenue Growth: 5.22%
• EPS Growth: 23.27%
• Country: IL
• Employees: 420
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 29.95
• Shares Outstanding: 57,681,590
• 10 Day Avg. Volume: 43,547
• 30 Day Avg. Volume: 62,856
• PEG Ratio: 0.31
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 2.07
• P/FCF Ratio: 9.03
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 6.45
• Enterprise Value/Gross Profit: 14.75
• Enterprise Value/Ebitda: 30.32
• 1Y Price Target: $3,611.91
• Price Target Upside: 63.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 115.03
• Revenue Forecast (FY): $58.80B

• Rating: 73 Outperform
• Price Target: 2,471.00 ▲(12.01% Upside)

Kamada's overall stock score is driven by its strong financial performance and positive earnings call, which highlight robust revenue growth and strategic product launches. However, technical indicators suggest bearish momentum, and valuation metrics indicate moderate attractiveness. Challenges such as declining royalties and slow clinical trial enrollment also weigh on the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Product Launches

Successful product launches diversify revenue streams and enhance market presence, contributing to sustainable growth.

Plasma Collection Expansion

Expansion of plasma collection facilities increases production capacity, supporting long-term supply and revenue stability.

Negative Factors

Decline in Glacia Royalties

Reduction in royalty income could impact revenue, necessitating increased sales from other products to maintain growth.

Below Plan Cytogam Sales

Underperformance in Cytogam sales indicates challenges in market penetration, potentially affecting future revenue targets.

Slow Clinical Trial Enrollment

Slow trial enrollment may delay product development timelines, impacting future growth and competitive positioning.

Kamada Business Overview & Revenue Model

Company Description

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

How the Company Makes Money

Kamada generates revenue primarily through the sale of its proprietary plasma-derived therapies, which are marketed and sold to hospitals, clinics, and healthcare providers. The company benefits from long-term supply agreements with global healthcare organizations, which provide a stable revenue stream. In addition to direct product sales, Kamada engages in strategic partnerships and collaborations with other pharmaceutical companies for research and development, which can lead to milestone payments and royalties. These partnerships enhance its product portfolio and expand market reach, contributing significantly to its overall earnings.

Kamada Financial Statement Overview

Summary

Kamada demonstrates strong revenue growth and improving profitability, with a stable balance sheet and low leverage. However, there is room for improvement in cost management and free cash flow conversion.

Income Statement

Kamada has demonstrated strong revenue growth with a TTM increase of 36.5% and consistent improvement in profitability metrics such as gross profit margin and net profit margin. The EBIT and EBITDA margins have also shown positive trends, indicating operational efficiency. However, the net profit margin remains moderate, suggesting room for improvement in cost management.

Balance Sheet

The company's balance sheet is stable with a low debt-to-equity ratio of 0.044, indicating conservative leverage. Return on equity has improved over time, reflecting better profitability. However, the equity ratio suggests a moderate level of equity financing, which could be optimized further.

Cash Flow

Kamada's cash flow performance is mixed, with a recent decline in free cash flow growth. The operating cash flow to net income ratio is strong, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio suggests potential challenges in converting profits into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	174.79M	160.95M	142.52M	129.34M	103.64M	133.25M
Gross Profit	76.47M	69.97M	55.49M	46.70M	30.33M	47.55M
EBITDA	37.20M	27.80M	21.53M	16.69M	4.01M	23.73M
Net Income	20.44M	14.46M	8.28M	-2.32M	-2.23M	17.14M
Balance Sheet
Total Assets	377.21M	372.25M	354.91M	322.38M	318.67M	210.66M
Cash, Cash Equivalents and Short-Term Investments	72.00M	78.44M	55.64M	34.26M	18.59M	109.27M
Total Debt	11.47M	11.06M	8.82M	20.60M	24.35M	4.94M
Total Liabilities	111.98M	112.79M	110.89M	146.36M	141.84M	32.03M
Stockholders Equity	265.23M	259.46M	244.02M	176.02M	176.82M	178.64M
Cash Flow
Free Cash Flow	18.33M	36.85M	-1.53M	24.80M	-12.55M	13.62M
Operating Cash Flow	28.32M	47.59M	4.32M	28.59M	-8.82M	19.11M
Investing Cash Flow	-9.99M	-10.74M	-5.84M	-3.78M	-61.05M	-13.13M
Financing Cash Flow	-17.87M	-13.91M	22.68M	-9.34M	18.59M	23.36M

Kamada Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2206.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:KMDA, the sentiment is Negative. The current price of 2206 is below the 20-day moving average (MA) of 2251.10, below the 50-day MA of 2272.92, and below the 200-day MA of 2431.44, indicating a bearish trend. The MACD of -16.36 indicates Positive momentum. The RSI at 42.65 is Neutral, neither overbought nor oversold. The STOCH value of 9.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:KMDA.

Kamada Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KMDA	73 Outperform	$1.27B	17.41	7.86%	―	5.22%	23.27%
BWAY	72 Outperform	1.02B	47.94	10.95%	―	21.13%	251.25%
TEVA	61 Neutral	94.48B	41.15	―	―	-5.10%	―
NVLG	56 Neutral	655.96M	32.67	―	2.97%	22.79%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Kamada Corporate Events

Kamada Ltd. Reports Strong Q3 2025 Financial Results with 30% Profit Growth

Kamada Ltd. reported strong financial results for the third quarter and first nine months of 2025, with a significant increase in profitability. The company achieved a 13% year-over-year revenue growth in the third quarter, reaching $47 million, and a 34% increase in adjusted EBITDA. For the first nine months, revenues rose by 11% to $135.8 million, with a 35% increase in adjusted EBITDA. Kamada’s financial performance is supported by its diverse product portfolio and strategic business development initiatives. The company maintains a positive outlook for the remainder of 2025, reiterating its full-year revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million. Kamada is also advancing its clinical trials and expanding its plasma collection operations, including receiving FDA approval for its Houston facility.

The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs2519.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

Kamada Initiates Clinical Trial for CYTOGAM in Kidney Transplantation

Kamada Ltd. announced the enrollment of the first patient in a clinical trial for CYTOGAM®, aimed at preventing late Cytomegalovirus (CMV) infection in kidney transplant recipients. This study, known as SHIELD, seeks to address the unmet medical need for reducing late CMV disease risk in high-risk transplant patients, potentially improving outcomes. The trial is supported by Kamada and led by experts in transplant-related infections, highlighting the company’s commitment to the transplant community and its strategic focus on innovative prophylactic approaches.

The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs2519.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

Kamada Ltd. Announces Annual General Meeting for December 2025

Kamada Ltd. announced it will hold its Annual General Meeting of Shareholders on December 10, 2025, in Rehovot, Israel. The meeting will address several key proposals, including the re-election of board members, approval of options for the CEO, amendments to the compensation policy, and changes to the Articles of Association to enhance indemnification and insurance for directors and officers. Additionally, the re-appointment of Kost Forer Gabbay & Kasierer as independent auditors will be ratified. These decisions are crucial for maintaining corporate governance and ensuring compliance with Israeli laws, potentially impacting shareholder value and the company’s operational framework.

The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs11.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

Kamada Ltd. Engages Investors at September Conferences

On September 2, 2025, Kamada Ltd. announced its participation in two major investor conferences: the 2025 Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. CEO Amir London will present and hold one-on-one meetings with investors. This participation underscores Kamada’s proactive engagement with the investment community, potentially enhancing its market visibility and attracting new investment opportunities.

The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs2713.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

Kamada Ltd’s Earnings Call: Positive Growth and Strategic Initiatives

Kamada Ltd’s recent earnings call conveyed a generally positive sentiment, underscoring the company’s robust revenue and EBITDA growth, alongside increased financial guidance. The call highlighted successful strategic initiatives, including biosimilar launches and plasma center expansion. However, challenges such as a decrease in gross profit margin and tax rate fluctuations were noted as areas requiring attention.

Kamada Ltd. Reports Strong 2025 Financial Growth

Kamada Ltd. is a global biopharmaceutical company specializing in plasma-derived therapies for rare and serious conditions, with a strong presence in the specialty plasma-derived field. In its latest earnings report, Kamada announced robust financial results for the second quarter and first half of 2025, highlighting an 11% year-over-year increase in total revenues and a 35% rise in adjusted EBITDA. The company reported first-half revenues of $88.8 million and adjusted EBITDA of $22.5 million, reflecting a 25% margin of revenues. Kamada also announced FDA approval for its plasma collection center in Houston, Texas, which is set to begin commercial sales, and emphasized its focus on securing commercial-stage business development opportunities. Looking ahead, Kamada has raised its full-year profitability guidance, expecting adjusted EBITDA between $40 million and $44 million, while maintaining its revenue guidance of $178 million to $182 million for 2025. The company continues to invest in strategic growth pillars, including organic growth, business development, and plasma collection operations, to support long-term profitable growth.

Kamada Ltd. Reports Strong Financial Results and FDA Approval in August 2025

Kamada Ltd. reported strong financial results for the second quarter and first half of 2025, with an 11% year-over-year increase in total revenues to $88.8 million and a 35% rise in adjusted EBITDA to $22.5 million. The company raised its full-year profitability guidance and announced FDA approval for its plasma collection center in Houston, Texas, which is expected to significantly contribute to its revenue. Kamada continues to focus on business development opportunities and advancing its clinical trials to support long-term growth.

The most recent analyst rating on (IL:KMDA) stock is a Hold with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

Kamada’s Houston Plasma Center Gains FDA Approval

On August 11, 2025, Kamada Ltd. announced that the FDA approved its plasma collection center in Houston, Texas, allowing it to commence commercial sales of normal source plasma. The facility, which has an annual collection capacity of approximately 50,000 liters, is expected to contribute $8 million to $10 million in annual revenue at full capacity. This approval strengthens Kamada’s position in the specialty plasma market, with the Houston center anticipated to be one of the largest in the U.S. for specialty plasma collection. Kamada plans to seek further approval from the European Medicines Agency for this site, enhancing its operational capabilities and market reach.

The most recent analyst rating on (IL:KMDA) stock is a Hold with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.